Commentary - International Journal of Respiratory Medicine (2023) Volume 8, Issue 2

Eosinophilic Lung Diseases: Understanding the Relationship with Allergic Bronco pulmonary Aspergillosis

Department of Medicine, National University Hospital, Singapore

*Corresponding Author:

Fatemeh Wang
Department of Medicine
National University Hospital, Singapore
E-mail: wangfmeh@nuhs.edu.sg

Received: 03-Apr-2023, Manuscript No. AAIJRM-23-97049; Editor assigned: 07-Apr-2023, PreQC No. AAIJRM-23-97049(PQ); Reviewed: 21-Apr-2023, QC No. AAIJRM-23-97049; Revised: 25-Apr-2023, Manuscript No. AAIJRM-23-97049(R); Published: 28-Apr-2023, DOI: 10.35841/aaijrm-8.2.144

Citation: Wang F. Eosinophilic Lung Diseases: Understanding the Relationship with Allergic Bronco pulmonary Aspergillosis. Int J Respir Med. 2023;8(2):144

Abstract

Allergic bronco pulmonary aspergillosis (ABPA) is a respiratory allergic disease that is characterized by an exaggerated immune response to the fungus Aspergillums, leading to inflammation and damage to the airways. ABPA is typically seen in individuals with asthma or cystic fibrosis (CF) and it can cause a range of respiratory symptoms and complications if left untreated. In this article, we will discuss the key aspects of ABPA, including its causes, symptoms, diagnosis and treatment

Keywords

Allergic, Pulmonary, Aspergillosis, Symptoms, Diagnosis, Treatment.

Introduction

Allergic bronco pulmonary aspergillosis (ABPA) is a common fungal infection in uncontrolled asthmatics, cystic fibrosis patients and immunocompromised patients. Early diagnosis and rapid implementation of proper management are critical to prevent complications and or disease progression. ABPA is caused by an immune response to Aspergillums, a common fungus found in the environment. In most people, the immune system effectively clears Aspergillums spores from the airways without any adverse effects. However, in individuals with asthma or CF, the immune response to Aspergillums can be exaggerated, leading to ABPA. The exact cause of this exaggerated immune response is not fully understood, but it is believed to involve a complex interplay between genetic, environmental and immune factors [1, 2].

The symptoms of ABPA can vary widely among individuals and may range from mild to severe. Common symptoms include wheezing, coughing, chest tightness, shortness of breath, and production of thick, sticky mucus. Some individuals may also experience fever, fatigue, and weight loss. ABPA can also lead to recurrent episodes of acute worsening of asthma symptoms, known as asthma exacerbations, which may require hospitalization. Over time, untreated ABPA can cause chronic inflammation and scarring of the airways, leading to irreversible lung damage [3].

Diagnosing ABPA can be challenging, as the symptoms of ABPA may overlap with those of other respiratory conditions, such as asthma or CF exacerbations. A thorough medical history, physical examination, and lung function tests are usually the first steps in the diagnostic process. Blood tests, including measurement of specific antibodies against Aspergillums, can provide supportive evidence for ABPA. Chest X-rays or computed tomography (CT) scans may show characteristic findings, such as bronchial wall thickening, mucus plugging, or airway dilation. In some cases, a bronchoscopy, which involves inserting a thin, flexible tube through the nose or mouth into the lungs, may be performed to collect sputum or tissue samples for further analysis. Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease that is caused by an allergic reaction to the fungus Aspergillums. It is a rare condition that affects people with asthma or cystic fibrosis [4].

The symptoms of ABPA can include wheezing, coughing, shortness of breath, and fever. These symptoms can be similar to those of asthma, so it is important to get an accurate diagnosis. The diagnosis of ABPA is made through a combination of symptoms, medical history, physical exam, and various tests, such as blood tests, skin tests, and imaging studies. The management of ABPA involves a multi-pronged approach that aims to reduce the inflammation caused by the immune response to Aspergillums and prevent complications. The cornerstone of treatment is corticosteroids, which are potent anti-inflammatory medications that help to suppress the immune response. Oral corticosteroids, such as prednisone, are usually prescribed initially at high doses and then tapered down over time based on the response to treatment. In some cases, inhaled corticosteroids may also be used as part of the treatment regimen for ABPA. Antifungal medications, such as itraconazole, may be used as adjunctive therapy to help reduce the Aspergillums burden in the airways. Other supportive measures, such as bronchodilators to relieve bronchial constriction and antibiotics to treat any bacterial infections, May also are prescribed as needed. In addition to medical treatment, management of ABPA also involves addressing any underlying conditions, such as asthma or CF. Optimizing asthma control, through the use of bronchodilators, inhaled corticosteroids, and other asthma medications, is crucial in managing ABPA in individuals with asthma. For individuals with CF, aggressive management of CF-related lung disease, including airway clearance techniques, antibiotics, and CFTR modulator medications, is important in controlling ABPA [5].

Conclusion

Treatment of ABPA usually involves a combination of medications, such as corticosteroids and antifungal drugs, as well as management of the underlying asthma or cystic fibrosis. With proper treatment, most people with ABPA can manage their symptoms and lead a normal life. In conclusion, ABPA is a rare lung disease that can be effectively treated with medication and management of the underlying condition. It is important to seek medical attention if you experience symptoms of ABPA or if you have asthma or cystic fibrosis and is at risk of developing the condition.

References

1. Abi Hatem N, Campbell S, Rubio E, et al. Meropenem: A possible new culprit in eosinophilic lung diseases. Lung India: Official Organ of Indian Chest Society. 2017;34(5):461.

Indexed at, Google Scholar, Cross Ref

2. Bernheim A, McLoud T. A review of clinical and imaging findings in eosinophilic lung diseases. American Journal of Roentgenology. 2017;208(5):1002-10.

Indexed at, Google Scholar, Cross Ref

3. Jeong YJ, Kim KI, Seo IJ, et al. Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics. 2007;27(3):617-37.

Indexed at, Google Scholar, Cross Ref

4. Samitas K, Radinger M, Bossios A. Current update on eosinophilic lung diseases and anti-IL-5 treatment. Recent Patents on Anti-Infective Drug Discovery. 2011;6(3):189-205.

Indexed at, Google Scholar, Cross Ref

5. Soler DG, Bennici A, Brunetto S, et al. Benralizumab in the management of rare primary eosinophilic lung diseases. InAllergy & Asthma Proceedings.2022;43:(6).

Indexed at, Google Scholar, Cross Ref